Congress · 117th Congress
Groups launch last-ditch effort against drug pricing changes
It recently announced a $1 million ad buy to run on D.C.-area cable channels from July 1 through Aug. 5.
Search Roll Call
Search the Roll Call archive by keyword, date, Congress, section, or tags.
10 results for "1"
Congress · 117th Congress
With Senate readying vote on insulin bill, advocates seek changes
and hopefully we can make it so that it’s going to have the biggest impact for the most people,” said Shaina Kasper, policy manager for T1International, a nonprofit that advocates for people with Type 1
Congress · 117th Congress
Democrats to meet on budget as moderate holdouts face pressure
DeFazio followed up in a Monday letter to colleagues committing to pass the Senate’s infrastructure bill by Oct. 1, when current surface transportation authorizations expire.
Policy · 116th Congress
Virus vaccination timeline depends on variety of factors
[jwp-video n=”1″] Number of doses and timing Vaccinating about 60 to 70 percent of the approximately 333 million U.S. residents — the percentage experts estimate need to be vaccinated in order
Policy · 116th Congress
COVID-19 trials risk excluding those most vulnerable to virus
[jwp-video n=”1″]
Policy · 116th Congress
FDA releases high coronavirus vaccine standards despite White House resistance
At the presidential debate in Cleveland last week, Trump said it’s possible there would be results before Nov. 1 and that “we’re going to deliver it right away.”
Policy · 116th Congress
Internal documents show drugmakers’ reliance on US price hikes
The hearings culminated from 18 months of investigations involving more than 1 million pages of company documents, the committee said.
Policy · 116th Congress
Experts: Public trust in science, data key to COVID-19 vaccine credibility
[jwp-video n=”1″]
Policy · 116th Congress
Corporations and consumer groups battle over COVID-19 liability
[jwp-video n=”1″] President Donald Trump said Tuesday he supports “curbs on frivolous litigation … a thing I know something about. There’s a lot of frivolous litigation.”
Policy · 116th Congress
FDA walks back Trump claims on COVID-19 drugs
[jwp-video n=”1″] Trump gave an optimistic timeline for the deployment of two treatments: remdesivir, an experimental HIV and antiviral drug that has not yet been approved by the FDA, and hydroxychloroquine